August 11, 2022 – PHILADELPHIA, PA. WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, today announced a licensing agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (“Janssen”). Under...
PHILADELPHIA and ST. LOUIS, MO and SAN DIEGO, June 15, 2022 /PRNewswire/ — WuXi Advanced Therapies (WuXi ATU), a global Contract Testing, Development and Manufacturing Organization (CTDMO), and Wugen Inc., a clinical-stage biotechnology company based in St....
WuXi Advanced Therapies (WuXi ATU) announced that it has successfully passed the European Union (EU) Qualified Person (QP) Audit and received the QP Statement supporting the facility in Wuxi City, China. This audit verifies that WuXi ATU’s Wuxi City site has...
28 April 2022 – SINGAPORE. WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, and A*STAR’s Bioprocessing Technology Institute (BTI), announced a new partnership to bring WuXi ATU’s proprietary Tetracycline-Enabled Self-Silencing Adenovirus...
Chimeric Therapeutics will leverage WuXi Advanced Therapies’ (“WuXi ATU”) closed loop CAR T platform and other capabilities to accelerate the clinical development of their CHM 1101 (CLTX CAR T) and CHM 2101 (CDH17 CAR T) programs for glioblastoma and gastrointestinal...
TESSA™ technology provides a scalable process for manufacturing gene therapies, accelerating the production of large quantities of therapeutic DNA required to treat patients in need New data published in Nature Communications supports the benefits of this technology...
